Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047421 | 0.89 | SCD (0.59) | SCDRAB9ATP53HDAC1TSHR | |
| SCHEMBL14047625 | 0.87 | SCD (0.57) | SCDRAB9ATP53HDAC1TSHR | |
| SCHEMBL14047400 | 0.87 | SCD (0.57) | SCDRAB9ATP53HDAC1TSHR | |
| SCHEMBL14047404 | 0.85 | SCD (0.47) | SCDRAB9ATP53HDAC1TSHR | |
| SCHEMBL14047603 | 0.82 | SCD (0.57) | SCDTSHRSMN1; SMN2KDM4ELMNA | |
| SCHEMBL14047539 | 0.81 | SCD (0.53) | SCDHDAC1KDM4EPOLB | |
| SCHEMBL14047595 | 0.79 | SCD (0.56) | SCDHDAC1 | |
| SCHEMBL14047532 | 0.76 | HDAC1 (0.44) | SCDHDAC1 | |
| SCHEMBL243619 | 0.75 | SCD (0.80) | SCD | |
| SCHEMBL14047531 | 0.72 | SCD (0.41) | SCDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |